Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512878 | 1.00 | LTA4H (0.54) | LTA4HTDP1PPARAPPARDCYP4F2 | |
| SCHEMBL1745109 | 0.82 | FFAR1 (0.69) | LTA4HTDP1CYP4F2CYP4A11S1PR1 | |
| SCHEMBL5208826 | 0.81 | CA12 (0.56) | TDP1PPARAPPARD | |
| SCHEMBL1752763 | 0.81 | FFAR1 (0.70) | LTA4HTDP1CYP4F2CYP4A11S1PR1 | |
| SCHEMBL8888665 | 0.80 | NR1H4 (0.57) | LTA4HPPARAPPARDPPARG | |
| SCHEMBL8888662 | 0.80 | NR1H4 (0.57) | LTA4HPPARAPPARDPPARG | |
| SCHEMBL4510808 | 0.80 | LTA4H (0.52) | LTA4HPPARAPPARDS1PR1S1PR3 | |
| SCHEMBL4510807 | 0.80 | LTA4H (0.52) | LTA4HPPARAPPARDS1PR1S1PR3 | |
| SCHEMBL4526042 | 0.80 | LTA4H (0.52) | LTA4HPPARAPPARDS1PR1S1PR3 | |
| SCHEMBL7999920 | 0.80 | ABCG2 (0.50) | LTA4HPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | LTA4H 281/4885TDP1 1511/4885PPARA 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.